Open Access Articles- Top Results for Thiocolchicoside


Systematic (IUPAC) name
Clinical data
AHFS/ International Drug Names
  • (Prescription only)
Oral, Topical, IM
Pharmacokinetic data
Bioavailability 25%[1]
Half-life 5-6 hours[1][2]
602-41-5 7pxY
PubChem CID 72067
UNII T1X8S697GT 7pxY
KEGG D07276 7pxY
ChEMBL CHEMBL1705373 7pxN
Chemical data
Formula C27H33NO10S
563.618 g/mol
 14pxN (what is this?)  (verify)

Thiocolchicoside (Muscoril, Myoril, Neoflax) is a muscle relaxant with anti-inflammatory and analgesic effects.[3][4][5][6] It acts as a competitive GABAA receptor antagonist and also glycine receptor antagonist with similar potency and nicotinic acetylcholine receptors to a much lesser extent.[7][8] It has powerful convulsant activity and should not be used in seizure-prone individuals.[9][10][11]

Side effects

Side effect of thiocolchicoside can include nausea, somnolence, allergy and vasovagal reactions.[12]

Although muscle relaxant have major side effect of Sedation, but Thiocholchicoside is free from sedation effect possible due to non-interference with nicotinic receptors.[citation needed]


Thiocolchicoside is broken down in the body to a metabolite called 3-demethylthiocolchicine (also known as SL59.0955 or M2) that could damage dividing cells therefore inducing toxicity in the embryo, neoplastic changes and fertility reduction in males.[citation needed] Therefore recommended oral dose should not exceed 7 days and intramuscular dose duration should not exceed 5 days.[medical citation needed] Local skin preparations are less toxic.


  1. ^ a b Perucca E, Poitou P, Pifferi G (1995). "Comparative pharmacokinetics and bioavailability of two oral formulations of thiocolchicoside, a GABA-mimetic muscle relaxant drug, in normal volunteers". European Journal of Drug Metabolism and Pharmacokinetics 20 (4): 301–5. PMID 8983937. doi:10.1007/bf03190249. 
  2. ^ Sandouk P, Bouvier d'Yvoire M, Chretien P, Tillement JP, Scherrmann JM (January 1994). "Single-dose bioavailability of oral and intramuscular thiocolchicoside in healthy volunteers". Biopharmaceutics & Drug Disposition 15 (1): 87–92. PMID 8161719. doi:10.1002/bdd.2510150108. 
  3. ^ Tüzün F, Unalan H, Oner N et al. (September 2003). "Multicenter, randomized, double-blinded, placebo-controlled trial of thiocolchicoside in acute low back pain". Joint, Bone, Spine : Revue Du Rhumatisme 70 (5): 356–61. PMID 14563464. doi:10.1016/S1297-319X(03)00075-7. 
  4. ^ Ketenci A, Basat H, Esmaeilzadeh S (July 2009). "The efficacy of topical thiocolchicoside (Muscoril) in the treatment of acute cervical myofascial pain syndrome: a single-blind, randomized, prospective, phase IV clinical study". Journal of the Turkish Society of Algology 21 (3): 95–103. PMID 19780000. 
  5. ^ Soonawalla DF, Joshi N (May 2008). "Efficacy of thiocolchicoside in Indian patients suffering from low back pain associated with muscle spasm". Journal of the Indian Medical Association 106 (5): 331–5. PMID 18839644. 
  6. ^ Ketenci A, Ozcan E, Karamursel S (July 2005). "Assessment of efficacy and psychomotor performances of thiocolchicoside and tizanidine in patients with acute low back pain". International Journal of Clinical Practice 59 (7): 764–70. PMID 15963201. doi:10.1111/j.1742-1241.2004.00454.x. 
  7. ^ Carta M, Murru L, Botta P et al. (September 2006). "The muscle relaxant thiocolchicoside is an agonist of GABAA receptor function in the central nervous system". Neuropharmacology 51 (4): 805–15. PMID 16806306. doi:10.1016/j.neuropharm.2006.05.023. 
  8. ^ Mascia MP, Bachis E, Obili N et al. (March 2007). "Thiocolchicoside inhibits the activity of various subtypes of recombinant GABA(A) receptors expressed in Xenopus laevis oocytes". European Journal of Pharmacology 558 (1-3): 37–42. PMID 17234181. doi:10.1016/j.ejphar.2006.11.076. 
  9. ^ De Riu PL, Rosati G, Sotgiu S, Sechi G (August 2001). "Epileptic seizures after treatment with thiocolchicoside". Epilepsia 42 (8): 1084–6. PMID 11554898. doi:10.1046/j.1528-1157.2001.0420081084.x. 
  10. ^ Giavina-Bianchi P, Giavina-Bianchi M, Tanno LK, Ensina LF, Motta AA, Kalil J (June 2009). "Epileptic seizure after treatment with thiocolchicoside". Therapeutics and Clinical Risk Management 5 (3): 635–7. PMC 2731019. PMID 19707540. doi:10.2147/tcrm.s4823. 
  11. ^ Sechi G, De Riu P, Mameli O, Deiana GA, Cocco GA, Rosati G (October 2003). "Focal and secondarily generalised convulsive status epilepticus induced by thiocolchicoside in the rat". Seizure : the Journal of the British Epilepsy Association 12 (7): 508–15. PMID 12967581. doi:10.1016/S1059-1311(03)00053-0. 
  12. ^ "Thiocolchicoside-induced liver injury". Mar 2011. Retrieved Dec 2014. 

Template:Navbox with collapsible sections